HEV-associated dendritic cells are observed in metastatic tumor-draining lymph nodes of cutaneous melanoma patients with longer distant metastasis-free survival after adjuvant immunotherapy

Front Immunol. 2023 Aug 25:14:1231734. doi: 10.3389/fimmu.2023.1231734. eCollection 2023.

Abstract

Introduction: Tissue biomarkers that aid in identifying cutaneous melanoma (CM) patients who will benefit from adjuvant immunotherapy are of crucial interest. Metastatic tumor-draining lymph nodes (mTDLN) are the first encounter site between the metastatic CM cells and an organized immune structure. Therefore, their study may reveal mechanisms that could influence patients´ outcomes.

Methods: Twenty-nine stage-III CM patients enrolled in clinical trials to study the vaccine VACCIMEL were included in this retrospective study. After radical mTDLN dissection, patients were treated with VACCIMEL (n=22) or IFNα-2b (n=6), unless rapid progression (n=1). Distant Metastasis-Free Survival (DMFS) was selected as an end-point. Two cohorts of patients were selected: one with a good outcome (GO) (n=17; median DMFS 130.0 months), and another with a bad outcome (BO) (n=12; median DMFS 8.5 months). We analyzed by immunohistochemistry and immunofluorescence the expression of relevant biomarkers to tumor-cell biology and immune cells and structures in mTDLN, both in the tumor and peritumoral areas.

Results: In BO patients, highly replicating Ki-67+ tumor cells, low tumor HLA-I expression and abundant FoxP3+ lymphocytes were found (p=0.037; p=0.056 and p=0.021). In GO patients, the most favorable biomarkers for prolonged DMFS were the abundance of peri- and intra-tumoral CD11c+ cells (p=0.0002 and p=0.001), peri-tumoral DC-LAMP+ dendritic cells (DCs) (p=0.001), and PNAd+ High Endothelial Venules (HEVs) (p=0.004). Most strikingly, we describe in GO patients a peculiar, heterogeneous structure that we named FAPS (Favoring Antigen-Presenting Structure), a triad composed of DC, HEV and CD62L+ naïve lymphocytes, whose postulated role would be to favor tumor antigen (Ag) priming of incoming naïve lymphocytes. We also found in GO patients a preferential tumor infiltration of CD8+ and CD20+ lymphocytes (p=0.004 and p=0.027), as well as peritumoral CD20+ aggregates, with no CD21+ follicular dendritic cells detected (p=0.023). Heterogeneous infiltration with CD64+CD68-CD163-, CD64+CD68+CD163- and CD64+CD68+CD163+ macrophages were observed in both cohorts.

Discussion: The analysis of mTDLN in GO and BO patients revealed marked differences. This work highlights the importance of analyzing resected mTDLN from CM patients and suggests a correlation between tumor and immune characteristics that may be associated with a spontaneous or vaccine-induced long DMFS. These results should be confirmed in prospective studies.

Keywords: cutaneous melanoma; dendritic cells; distant metastasis-free survival; high endothelial venules; metastatic tumor-draining lymph nodes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic
  • Adjuvants, Pharmaceutic
  • Dendritic Cells
  • Humans
  • Immunotherapy
  • Lymph Nodes
  • Melanoma* / therapy
  • Melanoma, Cutaneous Malignant
  • Prospective Studies
  • Retrospective Studies
  • Skin Neoplasms* / therapy
  • Venules

Substances

  • Adjuvants, Immunologic
  • Adjuvants, Pharmaceutic

Grants and funding

This work was supported by grants from Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (Agencia I+D); Instituto Nacional del Cáncer, Ministerio de Salud (INC-MSal); Fundación Sales, Fundación Cáncer FUCA; Fundación Pedro F. Mosoteguy, Argentina. The work was also supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne University, and in part by the Fondation ARC pour la recherche sur le cancer (PJA20181207895), France. The Phase I “VACCIMEL” study was sponsored by José Mordoh, M.D, and the Phase I study on “Dendritic cells loaded with apoptotic-necrotic tumor cells” was sponsored by Fundación Sales. The CASVAC-0401 clinical study was sponsored by Laboratorio Pablo Cassará S.R.L. Laboratorio Pabla Cassará was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. All authors declare no other competing interests.